• +1-646-491-9876
    • +91-20-67278686

    Search

    Liver Failure-Pipeline Review H1 2017

    Liver Failure-Pipeline Review H1 2017

    • Report Code ID: RW0001834397
    • Category Pharmaceuticals
    • No. of Pages 86
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

    Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy) , poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 1, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

    Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Liver Failure (Hepatic Insufficiency) - Overview
    Liver Failure (Hepatic Insufficiency) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
    Alfact Innovation
    BioLineRx Ltd
    Cell2B Advanced Therapeutics SA
    Conatus Pharmaceuticals Inc
    Immune Pharmaceuticals Inc
    Mina Therapeutics Ltd
    Mylan NV
    Ocera Therapeutics Inc
    PledPharma AB
    Promethera Biosciences SA
    Silence Therapeutics Plc
    Unicyte AG
    Ventria Bioscience
    Vital Therapies Inc
    Liver Failure (Hepatic Insufficiency) - Drug Profiles
    ALF-5755 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotide to Inhibit FAS for Liver Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotides to Inhibit MKK4 for Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BL-1220 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emricasan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    F-573 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HepaStem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ImmuneSafe - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MTL-CEBPA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide for Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ornithine phenylacetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PP-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    silibinin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VEN-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XEN-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Liver Failure (Hepatic Insufficiency) - Dormant Projects
    Liver Failure (Hepatic Insufficiency) - Discontinued Products
    Liver Failure (Hepatic Insufficiency) - Product Development Milestones
    Featured News & Press Releases
    Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
    Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
    Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
    Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
    Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
    Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
    Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
    Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
    Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting
    Apr 11, 2013: Gene inhibition helps to improve liver regeneration
    Apr 02, 2013: ALF-5755 phase II completion
    Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury
    Sep 04, 2012: Ventria Bioscience And University Of Colorado Receive NIH Grant To Study Treatment Of Acetaminophen Overdose-Induced Liver Failure
    Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure
    May 06, 2011: ALF-5755 phase II extends to germany
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Liver Failure (Hepatic Insufficiency) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H1 2017
    Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2017
    Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2017
    Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Liver Failure (Hepatic Insufficiency) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alfact Innovation
    BioLineRx Ltd
    Cell2B Advanced Therapeutics SA
    Conatus Pharmaceuticals Inc
    Immune Pharmaceuticals Inc
    Mina Therapeutics Ltd
    Mylan NV
    Ocera Therapeutics Inc
    PledPharma AB
    Promethera Biosciences SA
    Silence Therapeutics Plc
    Unicyte AG
    Ventria Bioscience
    Vital Therapies Inc

    Request for Sample

    Report Url http://www.reportsweb.com//liver-failure-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//liver-failure-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//liver-failure-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments